Navigation Links
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
Date:4/3/2013

MONTREAL, April 3, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Valeant and Obagi Medical Products, Inc. (NASDAQ: OMPI) have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013.  Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.

The offer documents will be amended to reflect the new offer price of $24.00 per share.  The expiration date of the tender offer will remain 12:00 midnight, New York City time, on April 23, 2013. The tender offer is conditioned on the tender of a majority of Obagi's shares calculated on a diluted basis, as well as the receipt of certain regulatory approvals and other customary closing conditions. Following the successful completion of the tender offer, a wholly owned subsidiary of Valeant will merge with Obagi and the outstanding Obagi shares not tendered in the tender offer will be converted into the right to receive the same $24.00 per share in cash paid in the tender offer.  Obagi's board of directors has unanimously approved the amended transaction.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, the pro
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Valeant Pharmaceuticals Announces Private Exchange Offer
2. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
3. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
4. Valeant Completes Acquisition Of Natur Produkt In Russia
5. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
6. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
7. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
8. Valeant Pharmaceuticals Announces New Management Appointments
9. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
10. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
11. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014  Bayer HealthCare will present data on ... th Annual Meeting, which takes place September 18-20 ... which will be shared through poster presentations, showcase Bayer,s ... Data will be presented in a scientific forum. ... in hemophilia A patients, Bayer is maintaining its commitment ...
(Date:9/17/2014)... -- Millions of people suffer from neck and arm pain as ... the FDA approved the launch of a clinical trial for ... by Spinal Kinetics, which may offer relief to people with ... Hospital for Special Surgery (HSS), the number one orthopedic hospital ... New York City and in the Northeast participating ...
(Date:9/17/2014)... , Sept. 17, 2014  Lightbeam Health Solutions ... Care Organization (Physician Direct ACO) to deploy the ... in providing better care while reducing costs. ... Physician Direct Accountable Care Organization is the ... (OPNS). The OPNS mission is to be the ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
... Results Further Validate Lipidomic-Based Therapeutics as an Emerging Area ... ... DIEGO, Sept. 4 Lpath, Inc. (OTC Bulletin,Board: LPTN), the ... in several murine models of human cancer,and AMD with Lpathomab(TM), ...
... HistoRx AQUA(R)-based assays to evaluate, clinical utility of protein ... ... -, NEW HAVEN, Conn., Sept. 4 HistoRx, Inc., ... the Radiation,Therapy Oncology Group (RTOG), a National Cancer Institute-funded clinical,cooperative ...
Cached Medicine Technology:Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 2Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 3HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3
(Date:9/17/2014)... is available in Spanish . ... than half of the population in our Community. Excess ... which affects liver function. Fat accumulates in the liver ... fibrosis and finally, cirrhosis. To date, the most reliable ... Imaging techniques such as abdominal ecography detect it but ...
(Date:9/17/2014)... West Orange, NJ. September 17, 2014. Kessler Foundation ... grants awarded by the International Progressive Multiple Sclerosis ... Neuropsychology, Neuroscience & Traumatic Brain Injury Research, is ... at the efficacy of cognitive rehabilitation in individuals ... of 22 research grants awarded by the Alliance ...
(Date:9/17/2014)... International Journal of Surgery ( IJS ) has announced ... content: after 24 months published journal issues become available for ... is to improve surgical knowledge and patient care and ... all will improve efforts to achieve this. , Professor ... has always been a great place for authors to publish ...
(Date:9/17/2014)... 2014 Elsevier, a world-leading provider of scientific, ... announced the publication of a position statement by ... the journal Maturitas on the topic ... the most prevalent cancer in women, with slightly ... Western countries. Mammography screening is a well-established method ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its 67th ... conference in the field of aging from November ... register free of charge. , An estimated 4,000 professionals ... Walter E. Washington Convention Center and Marriott Marquis Washington, ... Cells to Societies" and the program schedule contains more ...
Breaking Medicine News(10 mins):Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
... genetic disease that causes deafness and dumbness has hit a ... victims belong to Gujjar community. // ,Health and Medical ... that at least 72 cases of the disease have surfaced ... New born babies are also affected by the disease" ...
... the brain of mice were augmented, conditions similar to ... was reported by researchers from Stanford University Medical Centre ... in the treatment of this disease in humans. According ... a drug along with cannabis-like chemicals resulted in a ...
... genetic disease, genetics researchers have identified a novel biological ... development, potentially in cases of mental retardation and autism. ... two genes that contribute to Cornelia deLange syndrome (CdLS), ... in 10,000 children. The disease varies from milder to ...
... by x-ray crystallography. The bundle contains eight copies of ... like and unlike colors, respectively. ,Researchers ... found in natural proteins, discovering that they can form ... protein. Their findings could help scientists design drugs that ...
... According to one of the major findings of a ... less than children who sleep less, and they //are ... years later. The results of this new study were ... Child Development. ,Conducted by researchers at ...
... artemisinin-based combination therapies to prevent malaria //parasites from developing ... the National Agency for Food and Drug Administration and ... the parasite already has grown resistant to chloroquine and ... be difficult to find another malaria treatment. ...
Cached Medicine News:Health News:Gene Found for Rare Disorder May Reveal New Pathway in Mental Retardation 2Health News:Man-Made Proteins Could Be More Useful Than Real Ones 2Health News:Man-Made Proteins Could Be More Useful Than Real Ones 3Health News:Childhood Obesity Linked With Sleep 2
... CLIP 5 mm clip applier contains ... designed for introduction and use through ... sleeve, or larger with the use ... of the shaft is approximately 28 ...
Pilling-Weck, medium-large clip size, 10mm, rotatable take apart...
Insert only, Ethicon medium-large clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
Medicine Products: